Vulnerability of calbindin, calretinin and parvalbumin in a transgenic/knock-in APPswe/PS1dE9 mouse model of Alzheimer disease together with disruption of hippocampal neurogenesis

Experimental Gerontology

Volumn 69, Issue , 2015, Pages 176-188

  Verdaguer, Ester ^a   Brox, Susana ^a   Petrov, Dmitry ^a   Olloquequi, Jordi ^b   Romero, Rafael ^a   de Lemos, M Luisa ^a   Camins, Antoni ^a   Auladell, Carme ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

Author keywords

Alzheimer disease; APPswe PS1dE9 mouse; Calbindin; Calretinin; Hippocampus; Parvalbumin

Indexed keywords

CALBINDIN; CALRETININ; DOUBLECORTIN; NEURON SPECIFIC NUCLEAR PROTEIN; PARVALBUMIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APPSWE MOUSE; ARTICLE; BRAIN TISSUE; CELL METABOLISM; CELLULAR DISTRIBUTION; CLINICAL FEATURE; CONTROLLED STUDY; DENTATE GYRUS; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA3 REGION; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTERNEURON; MALE; MOUSE; MOUSE STRAIN; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PS1DE9 MOUSE; TRANSGENIC MOUSE; UPREGULATION; WILD TYPE MOUSE; ANIMAL; DISEASE COURSE; DISEASE MODEL; METABOLISM; NERVE CONDUCTION; NEUROFIBRILLARY TANGLE; PATHOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; CALBINDIN 2; CALBINDINS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HIPPOCAMPUS; MICE; MICE, TRANSGENIC; NEURAL CONDUCTION; NEUROFIBRILLARY TANGLES; NEUROGENESIS; NEURONAL PLASTICITY; PARVALBUMINS;

EID: 84969791903     PISSN: 05315565     EISSN: 18736815     Source Type: Journal    
DOI: 10.1016/j.exger.2015.06.013     Document Type: Article

References (56)

1. ábrahám H., Orsi G., Seress L. Ontogeny of cocaine- and amphetamine-regulated transcript (CART) peptide and calbindin immunoreactivity in granule cells of the dentate gyrus in the rat. Int. J. Dev. Neurosci. 2007, 25:265-274. 10.1016/j.ijdevneu.2007.05.008.
2. Baglietto-Vargas D., Moreno-Gonzalez I., Sanchez-Varo R., Jimenez S., Trujillo-Estrada L., Sanchez-Mejias E., Torres M., Romero-Acebal M., Ruano D., Vizuete M., Vitorica J., Gutierrez A. Calretinin interneurons are early targets of extracellular amyloid-beta pathology in PS1/A??PP Alzheimer mice hippocampus. J. Alzheimers Dis. 2010, 21:119-132. 10.3233/JAD-2010-100066.
3. Bai X., Edden R.A.E., Gao F., Wang G., Wu L., Zhao B., Wang M., Chan Q., Chen W., Barker P.B. Decreased γ-aminobutyric acid levels in the parietal region of patients with Alzheimer's disease. J. Magn. Reson. Imaging 2014, 00:1-6. 10.1002/jmri.24665.
4. Baimbridge K.G., Celio M.R., Rogers J.H. Calcium-binding proteins in the nervous system. Trends Neurosci. 1992, 15:303-308. 10.1016/0166-2236(92)90081-I.
5. Barinka F., Druga R. Calretinin expression in the mammalian neocortex: a review. Physiol. Res. 2010, 59:665-677.
6. Bilkei-Gorzo A. Genetic mouse models of brain ageing and Alzheimer's disease. Pharmacol. Ther. 2014, 142(2):244-257.
7. Borchelt D.R., Thinakaran G., Eckman C.B., Lee M.K., Davenport F., Ratovitsky T., Prada C.M., Kim G., Seekins S., Yager D., Slunt H.H., Wang R., Seeger M., Levey A.I., Gandy S.E., Copeland N.G., Jenkins N.A., Price D.L., Younkin S.G., Sisodia S.S. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 1996, 17:1005-1013. 10.1016/S0896-6273(00)80230-5.
8. Brady D.R., Mufson E.J. Parvalbumin-immunoreactive neurons in the hippocampal formation of Alzheimer's diseased brain. Neuroscience 1997, 80:1113-1125. 10.1016/S0306-4522(97)00068-7.
9. Brasnjevic I., Lardenoije R., Schmitz C., Van Der Kolk N., Dickstein D.L., Takahashi H., Hof P.R., Steinbusch H.W.M., Rutten B.P.F. Region-specific neuron and synapse loss in the hippocampus of APP(SL)/PS1 knock-in mice. Transl. Neurosci. 2013, 4:8-19. 10.2478/s13380-013-0111-8.
10. Brion J.P., Resibois A. A subset of calretinin-positive neurons are abnormal in Alzheimer's disease. Acta Neuropathol. 1994, 88:33-43. 10.1007/BF00294357.
11. Brown J.P., Couillard-Després S., Cooper-Kuhn C.M., Winkler J., Aigner L., Kuhn H.G. Transient expression of doublecortin during adult neurogenesis. J. Comp. Neurol. 2003, 467:1-10. 10.1002/cne.10874.
12. Casas C., Sergeant N., Itier J.-M., Blanchard V., Wirths O., van der Kolk N., Vingtdeux V., van de Steeg E., Ret G., Canton T., Drobecq H., Clark A., Bonici B., Delacourte A., Benavides J., Schmitz C., Tremp G., Bayer T.A., Benoit P., Pradier L. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am. J. Pathol. 2004, 165:1289-1300.
13. Cummings J.L., Cole G. Alzheimer disease. JAMA J. Am. Med. Assoc. 2002, 287:2335-2338. 10.1001/jama.287.18.2335.
14. D'Andrea M.R., Nagele R.G. Morphologically distinct types of amyloid plaques point the way to a better understanding of Alzheimer's disease pathogenesis. Biotech. Histochem. 2010, 85:133-147. 10.3109/10520290903389445.
15. Ferando I., Mody I. Interneuronal GABAA receptors inside and outside of synapses. Curr. Opin. Neurobiol. 2014, 10.1016/j.conb.2013.12.001.
16. Fujise N., Liu Y., Hori N., Kosaka T. Distribution of calretinin immunoreactivity in the mouse dentate gyrus: II. Mossy cells, with special reference to their dorsoventral difference in calretinin immunoreactivity. Neuroscience 1997, 82:181-200. 10.1016/S0306-4522(97)00261-3.
17. George Paxinos K.F. Paxinos and Franklin's the Mouse Brain in Stereotaxic Coordinates 2012, [WWW Document], Acad. Press, São Paulo, URL https://www.elsevier.com/books/paxinos-and-franklins-the-mouse-brain-in-stereotaxic-coordinates/paxinos/978-0-12-391057-8.
18. Gsell W., Jungkunz G., Riederer P. Functional neurochemistry of Alzheimer's disease. Curr. Pharm. Des. 2004, 10:265-293. 10.2174/1381612043386473.
19. Gulyás A.I., Hájos N., Freund T.F. Interneurons containing calretinin are specialized to control other interneurons in the rat hippocampus. J. Neurosci. 1996, 16:3397-3411.
20. Hof P.R., Morrison J.H. The aging brain: morphomolecular senescence of cortical circuits. Trends Neurosci. 2004, 27:607-613. 10.1016/j.tins.2004.07.013.
21. Hof P.R., Nimchinsky E.A., Celio M.R., Bouras C., Morrison J.H. Calretinin-immunoreactive neocortical interneurons are unaffected in Alzheimer's disease. Neurosci. Lett. 1993, 152:145-148. 10.1016/0304-3940(93)90504-E.
22. Houser C.R. Interneurons of the dentate gyrus: an overview of cell types, terminal fields and neurochemical identity. Prog. Brain Res. 2007, 10.1016/S0079-6123(07)63013-1.
23. Iacopino A., Christakos S., German D., Sonsalla P.K., Altar C.A. Calbindin-D28K-containing neurons in animal models of neurodegeneration: possible protection from excitotoxicity. Brain Res. Mol. Brain Res. 1992, 13:251-261. 10.1016/0169-328X(92)90033-8.
24. Iritani S., Niizato K., Emson P.C. Relationship of calbindin D28K-immunoreactive cells and neuropathological changes in the hippocampal formation of Alzheimer's disease. Neuropathology 2001, 21:162-167. 10.1046/j.1440-1789.2001.00393.x.
25. Iwakiri M., Mizukami K., Ikonomovic M.D., Ishikawa M., Abrahamson E.E., Dekosky S.T., Asada T. An immunohistochemical study of GABA A receptor gamma subunits in Alzheimer's disease hippocampus: relationship to neurofibrillary tangle progression. Neuropathology 2009, 29:263-269. 10.1111/j.1440-1789.2008.00978.x.
26. Jankowsky J.L., Slunt H.H., Gonzales V., Jenkins N.A., Copeland N.G., Borchelt D.R. APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1. Neurobiol. Aging 2004, 25:885-892. 10.1016/j.neurobiolaging.2003.09.008.
27. Jinno S., Kosaka T. Patterns of expression of calcium binding proteins and neuronal nitric oxide synthase in different populations of hippocampal GABAergic neurons in mice. J. Comp. Neurol. 2002, 449:1-25. 10.1002/cne.10251.
28. Jinno S., Kosaka T. Cellular architecture of the mouse hippocampus: a quantitative aspect of chemically defined GABAergic neurons with stereology. Neurosci. Res. 2006, 10.1016/j.neures.2006.07.007.
29. Jinno S., Kosaka T. Stereological estimation of numerical densities of glutamatergic principal neurons in the mouse hippocampus. Hippocampus 2010, 20:829-840. 10.1002/hipo.20685.
30. Junyent F., Utrera J., Auladell C. Axonal retraction and regeneration induced by N, N-diethyldithiocarbamate (DEDTC) in the central nervous system. Eur. J. Neurosci. 2006, 24(11):3163-3173.
31. Klausberger T., Somogyi P. Neuronal diversity and temporal dynamics: the unity of hippocampal circuit operations. Science 2008, 321:53-57. 10.1126/science.1149381.
32. Kook S.-Y., Jeong H., Kang M.J., Park R., Shin H.J., Han S.-H., Son S.M., Song H., Baik S.H., Moon M., Yi E.C., Hwang D., Mook-Jung I. Crucial role of calbindin-D28k in the pathogenesis of Alzheimer's disease mouse model. Cell Death Differ. 2014, 1-13. 10.1038/cdd.2014.67.
33. Krezymon A., Richetin K., Halley H., Roybon L., Lassalle J.M., Francès B., Verret L., Rampon C. Modifications of hippocampal circuits and early disruption of adult neurogenesis in the Tg2576 mouse model of Alzheimer's disease. PLoS One 2013, 8. 10.1371/journal.pone.0076497.
34. Mann E.O., Mody I. Control of hippocampal gamma oscillation frequency by tonic inhibition and excitation of interneurons. Nat. Neurosci. 2010, 13:205-212. 10.1038/nn.2464.
35. Mattson M.P. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol. Rev. 1997, 77:1081-1132.
36. Mikkonen M., Alafuzoff I., Tapiola T., Soininen H., Miettinen R. Subfield- and layer-specific changes in parvalbumin, calretinin and calbindin-D28k immunoreactivity in the entorhinal cortex in Alzheimer's disease. Neuroscience 1999, 92:515-532. 10.1016/S0306-4522(99)00047-0.
37. Minogue A.M., Jones R.S., Kelly R.J., McDonald C.L., Connor T.J., Lynch M.A. Age-associated dysregulation of microglial activation is coupled with enhanced blood-brain barrier permeability and pathology in APP/PS1 mice. Neurobiol. Aging 2014, 35:1442-1452. 10.1016/j.neurobiolaging.2013.12.026.
38. Molinari S., Battini R., Ferrari S., Pozzi L., Killcross A.S., Robbins T.W., Jouvenceau A., Billard J.M., Dutar P., Lamour Y., Baker W.A., Cox H., Emson P.C. Deficits in memory and hippocampal long-term potentiation in mice with reduced calbindin D28K expression. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:8028-8033. 10.1073/pnas.93.15.8028.
39. Moon M., Cha M.Y., Mook-Jung I. Impaired hippocampal neurogenesis and its enhancement with ghrelin in 5XFADl. J. Alzheimers Dis. 2014, 41:233-241. 10.3233/JAD-132417.
40. Olloquequi J., Ferrer J., Montes J.F., Rodríguez E., Montero M.A., García-Valero J. Differential lymphocyte infiltration in small airways and lung parenchyma in COPD patients. Respir. Med. 2010, 104(9):1310-1318.
41. Palop J.J., Jones B., Kekonius L., Chin J., Yu G.-Q., Raber J., Masliah E., Mucke L. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:9572-9577. 10.1073/pnas.1133381100.
42. Palop J.J., Chin J., Roberson E.D., Wang J., Thwin M.T., Bien-Ly N., Yoo J., Ho K.O., Yu G.Q., Kreitzer A., Finkbeiner S., Noebels J.L., Mucke L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 2007, 55:697-711. 10.1016/j.neuron.2007.07.025.
43. Popović M., Caballero-Bleda M., Kadish I., van Groen T. Subfield and layer-specific depletion in calbindin-D28K, calretinin and parvalbumin immunoreactivity in the dentate gyrus of amyloid precursor protein/presenilin 1 transgenic mice. Neuroscience 2008, 155:182-191. 10.1016/j.neuroscience.2008.05.023.
44. Sampson V.L., Morrison J.H., Vickers J.C. The cellular basis for the relative resistance of parvalbumin and calretinin immunoreactive neocortical neurons to the pathology of Alzheimer's disease. Exp. Neurol. 1997, 145:295-302. 10.1006/exnr.1997.6433.
45. Stefanits H., Wesseling C., Kovacs G.G. Loss of Calbindin immunoreactivity in the dentate gyrus distinguishes Alzheimer's disease from other neurodegenerative dementias. Neurosci. Lett. 2014, 566:137-141. 10.1016/j.neulet.2014.02.026.
46. Streit W.J. Microglial activation and neuroinflammation in Alzheimer's disease: a critical examination of recent history. Front. Aging Neurosci. 2010, 2.
47. Streit W.J., Mrak R.E., Griffin W.S.T. Microglia and neuroinflammation: a pathological perspective. J. Neuroinflammation 2004, 1:14. 10.1186/1742-2094-1-14.
48. Takahashi H., Brasnjevic I., Rutten B.P.F., Van Der Kolk N., Perl D.P., Bouras C., Steinbusch H.W.M., Schmitz C., Hof P.R., Dickstein D.L. Hippocampal interneuron loss in an APP/PS1 double mutant mouse and in Alzheimer's disease. Brain Struct. Funct. 2010, 214:145-160. 10.1007/s00429-010-0242-4.
49. Tatebayashi Y. The dentate gyrus neurogenesis: a common therapeutic target for Alzheimer disease and senile depression?. Seishin Shinkeigaku Zasshi 2003, 105:398-404.
50. Van Groen T., Kiliaan A.J., Kadish I. Deposition of mouse amyloid β in human APP/PS1 double and single AD model transgenic mice. Neurobiol. Dis. 2006, 23:653-662. 10.1016/j.nbd.2006.05.010.
51. Verret L., Mann E.O., Hang G.B., Barth A.M.I., Cobos I., Ho K., Devidze N., Masliah E., Kreitzer A.C., Mody I., Mucke L., Palop J.J. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in alzheimer model. Cell 2012, 149:708-721. 10.1016/j.cell.2012.02.046.
52. Wang J., Tanila H., Puoliväli J., Kadish I., Van Groen T. Gender differences in the amount and deposition of amyloidβ in APPswe and PS1 double transgenic mice. Neurobiol. Dis. 2003, 14:318-327. 10.1016/j.nbd.2003.08.009.
53. Wilcock G.K., Esiri M.M., Bowen D.M., Smith C.C. Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J. Neurol. Sci. 1982, 57:407-417.
54. Wirths O., Breyhan H., Schafer S., Roth C., Bayer T.A. Deficits in working memory and motor performance in the APP/PS1ki mouse model for Alzheimer's disease. Neurobiol. Aging 2008, 29:891-901. 10.1016/j.neurobiolaging.2006.12.004.
55. Yu J.-T., Chang R.C.-C., Tan L. Calcium dysregulation in Alzheimer's disease: from mechanisms to therapeutic opportunities. Prog. Neurobiol. 2009, 89:240-255. 10.1016/j.pneurobio.2009.07.009.
56. Zahs K.R., Ashe K.H. 'Too much good news'-are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease?. Trends Neurosci. 2010, 33(8):381-389.